News

Providence Cancer Institute in partnership with AIM at Melanoma present a free online event designed to educate and empower patients and care partners affected by melanoma.

A new study approach reflects a deeper understanding of cancer at the molecular level and marks a shift away from one-size-fits-all treatments.

Free educational presentations from Providence Senior Health are taking place in September in Beaverton, Hillsboro, Seaside and Medford. See the schedule and registration information.

Dr. Allie Grossmann’s new lab at Earle A. Chiles Research Institute is focused on understanding how tumors communicate with their environment, grow, survive and spread.

“For my patients.” “For my friend’s daughter.” “For the challenge.” “For the cure.” Providence runners and walkers share why they’re doing the relay – and helping raise funds to #FINISHCANCER.

Dr. Walter Urba, a pioneer and key figure in the development of immunotherapy, will retire from Providence Cancer Institute at the end of year.

Prominent cancer scientist Dr. Bernard Fox recognized for his work to advance the field of cancer immunotherapy through increasing public understanding, awareness and research efforts.

A new medication may help people with KRAS G12C-mutant non-small cell lung cancer. Read about the study and a trial evaluating an immunotherapy for treating head and neck squamous cell carcinoma.

Cancer survivor Mark Williams chats with Dr. Brendan Curti about

What motivates the co-captains of the FINISHCANCER caregiver team to commit their time to running this remarkable relay? Read what they say about preparing for the race and what inspires them to run.

Although chemotherapy is the cornerstone treatment for triple negative breast cancer, survival outcomes remain disappointing. Two studies could help improve treatment options.